Proteomics in prostate cancer

Purpose of review State-of-the-art proteomics technologies are currently being assessed for utility in the study of prostatic malignancy. This review aims to provide background information on the current proteomics techniques employed in prostate cancer research, recent reports showing the potential application of proteomics in urological practice, and the future direction of proteomics in prostate cancer research and management. Recent findings Proteomic profiling of serum as a diagnostic tool and a platform for biomarker discovery in prostate cancer continues to draw favorable attention as well as close scrutiny as technological enhancements and multi-center study results are reported. In-vitro studies on prostate cell lines provide positive proof-of-principle results. The application of proteomics to query prostate tissue specimens yields novel prostate cancer biomarkers requiring further validation. The integration of proteomics with immunology also yields promising findings that may translate into clinically relevant biological assays. Summary The study of proteomics is an emerging research field, and current studies continue to display potential future usage in prostate cancer management. Succeeding scientific investigations will probably yield new diagnostic and prognostic tools for prostate cancer, provide insights into its underlying biology, and contribute to the development of novel treatment strategies.

[1]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[2]  L. Liotta,et al.  Laser Capture Microdissection , 1996, Science.

[3]  M. Kremer,et al.  Laser Capture Microdissection: Methodical Aspects and Applications with Emphasis on Immuno-Laser Capture Microdissection , 2001, Pathobiology.

[4]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[5]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[6]  Debashis Ghosh,et al.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.

[7]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[8]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[9]  George L. Wright,et al.  SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. , 2002, Expert review of molecular diagnostics.

[10]  Bao-Ling Adam,et al.  Diagnostic potential of serum proteomic patterns in prostate cancer. , 2003, The Journal of urology.

[11]  G. V. Van Berkel.  An Overview of Some Recent Developments in Ionization Methods for Mass Spectrometry , 2003, European journal of mass spectrometry.

[12]  Min Zhan,et al.  A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.

[13]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[14]  K. Dooley.  Tandem mass spectrometry in the clinical chemistry laboratory. , 2003, Clinical biochemistry.

[15]  Emanuel F Petricoin,et al.  Protein microarrays: meeting analytical challenges for clinical applications. , 2003, Cancer cell.

[16]  Jeffrey S. Morris,et al.  Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..

[17]  Emanuel F Petricoin,et al.  Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. , 2004, The Journal of urology.

[18]  L. M. Glodé,et al.  A comprehensive characterization of the peptide and protein constituents of human seminal fluid , 2004, The Prostate.

[19]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[20]  Daniel W Chan,et al.  Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. , 2004, The Journal of urology.

[21]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[22]  R W Veltri,et al.  Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI‐TOF , 2004, The Prostate.

[23]  Debashis Ghosh,et al.  Humoral Immune Response to α-Methylacyl-CoA Racemase and Prostate Cancer , 2004 .

[24]  D. Ornstein,et al.  Proteomics to diagnose human tumors and provide prognostic information. , 2004, Oncology.

[25]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[26]  W. Isaacs,et al.  Improved biomarkers for prostate cancer: a definite need. , 2004, Journal of the National Cancer Institute.

[27]  Daniel B. Martin,et al.  Quantitative Proteomic Analysis of Proteins Released by Neoplastic Prostate Epithelium , 2004, Cancer Research.

[28]  E. Petricoin,et al.  An investigation into the human serum “interactome” , 2004, Electrophoresis.

[29]  L. Cazares,et al.  Selective capture of prostatic basal cells and secretory epithelial cells for proteomic and genomic analysis. , 2004, Urologic oncology.

[30]  S. Ho,et al.  Monitoring the serological proteome: the latest modality in prostate cancer detection. , 2004, The Journal of urology.

[31]  M. Gleave,et al.  Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis , 2004, Cancer Research.

[32]  D. L. Diamond,et al.  Analysis of prostate cancer by proteomics using tissue specimens. , 2005, The Journal of urology.

[33]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[34]  M. Trosset,et al.  Enhancement of sensitivity and resolution of surface-enhanced laser desorption/ionization time-of-flight mass spectrometric records for serum peptides using time-series analysis techniques. , 2005, Clinical chemistry.

[35]  L. Nan,et al.  EX VIVO EXPANDED HUMAN Vλ9Vδ2+ λδ-T CELLS MEDIATE INNATE ANTITUMOR ACTIVITY AGAINST HUMAN PROSTATE CANCER CELLS IN VITRO , 2005 .

[36]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[37]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.